Preprint
Article

Can Latency-Reversing Drugs Reawaken Dormant Retrovirus Infection?A Mathematical Analysis

Altmetrics

Downloads

583

Views

564

Comments

1

A peer-reviewed article of this preprint also exists.

S Chen  *

This version is not peer-reviewed

Submitted:

08 April 2022

Posted:

11 April 2022

Read the latest preprint version here

Alerts
Abstract
The technique of using drugs to target latent virus reservoir has been introduced to reawaken the dormant virus so that the immune system can attack it. However, further tests have shown this method to fail in laboratory tests. In this work, the author tries to mathematically analyze whether drugs can be used to reawaken dormant virus reservoirs. The study uses mathematical formulas to differentiate between different relationship types between sets of elements, and then a model of protein reawakening dormant reservoirs is presented. The results show that the amino acid sequences ARG of gag proteins of HTLV1, HTLV2, STLV1 and STLV2 match with their primer binding site GGGGGCTCG in the 3'-to-5' direction, and the amino acid sequences SPR of gag proteins of HIV1, HIV2, SIV and FIV match with their primer binding site GGCGCCCGA in the 3'-to-5' direction. The gag, gag-pol and gag-pro-pol proteins are promising for reawakening dormant retrovirus infection. The author hence believes that the latency-reversing drugs were involved in the process of transcription of cancer, and the genome they reawakened just happened to contain the genome of the retrovirus, which means that it was false reawakening. On the other hand, using proteins of retroviruses to reawaken them is more reliable, just like androgen receptor activates the IGF1R gene.
Keywords: 
Subject: Biology and Life Sciences  -   Virology
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2024 MDPI (Basel, Switzerland) unless otherwise stated